BioGene Therapeutics Inc. Appoints Dr. Kamal Albarazanji as Senior Director of Metabolic Research

Core Insights - BioGene Therapeutics Inc. has appointed Dr. Kamal Albarazanji as Senior Director of Metabolic Research effective August 18, 2025, to enhance its research capabilities in metabolic health [1][4]. Company Overview - PreveCeutical Medical Inc. is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature-identical products, with five ongoing research and development programs targeting diabetes, obesity, and other health issues [5]. - BioGene Therapeutics Inc. is a Texas-based life sciences company dedicated to advancing therapies in metabolic health and gene-based treatments, with a subsidiary in Australia benefiting from a 43.5% R&D tax cashback incentive [7]. Dr. Kamal Albarazanji's Background - Dr. Albarazanji has extensive expertise in in vivo pharmacology, target validation, and translational research, having previously worked on programs related to metabolic diseases and cardiovascular health at a leading pharmaceutical company [2]. - He has a notable history at SmithKline Beecham (now GSK), contributing to significant advancements in hypertension and obesity treatments [2]. - Dr. Albarazanji holds numerous patents and has authored over 20 peer-reviewed manuscripts in prestigious journals, showcasing his prolific research contributions [3]. Strategic Importance - The appointment of Dr. Albarazanji is expected to accelerate BioGene's pipeline of innovative therapeutics, aligning with the company's mission to address unmet needs in obesity and diabetes [4]. - Dr. Albarazanji's vision and expertise are anticipated to enhance the company's research programs and lead to meaningful outcomes for patients [4].